compound 2 [PMID: 28621538]   Click here for help

GtoPdb Ligand ID: 11282

Synonyms: example 727 [WO2012093101A1]
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Compound 2 is a small molecule complement factor D inhibitor that has been developed by Novartis [1]. The compound is orally bioavailable, and blocks activation of the complement alternative pathway in vitro and in vivo. Factor D inhibitors act upstream of the factor C5-targeting drugs such as eculizumab and ravulizumab, and small molecules are intended to offer more flexible therapeutic options than the existing monoclonal antibodies.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 123.21
Molecular weight 482.07
XLogP 1.84
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Brc1cccc(n1)NC(=O)[C@@H]1C[C@@H]2[C@H](N1C(=O)Cn1nc(c3c1cccc3)C(=O)N)C2
Isomeric SMILES Brc1cccc(n1)NC(=O)[C@@H]1C[C@@H]2[C@H](N1C(=O)Cn1nc(c3c1cccc3)C(=O)N)C2
InChI InChI=1S/C21H19BrN6O3/c22-16-6-3-7-17(24-16)25-21(31)15-9-11-8-14(11)28(15)18(29)10-27-13-5-2-1-4-12(13)19(26-27)20(23)30/h1-7,11,14-15H,8-10H2,(H2,23,30)(H,24,25,31)/t11-,14-,15+/m1/s1
InChI Key CWZUTHDJLNZLCM-DFBGVHRSSA-N
Immunopharmacology Comments
Inhibition of factor D is an attractive mechanism to block the activation of the alternative complement pathway of the innate immune system with high specificity and efficiency, and offers therapeutic potential for range of complement-mediated conditions. Compound 2 is a selective factor D inhibitor [1]. It inhibits membrane attack complex (MAC) formation in vitro (IC50 50 nM) and in vivo (in a mouse model of LPS-induced systemic alternative complement pathway activation; the mice expressing human factor D).